DIAMOND KRISTINE
Known title: Chief Accounting OfficerCIK: 0001804665
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 218 | $0 | 10/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 79 | $23K | 10/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 218 | $0 | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 79 | $22K | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 78 | $18K | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 204 | $0 | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 203 | $0 | 1/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 84 | $18K | 1/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 204 | $0 | 10/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 73 | $15K | 10/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 73 | $13K | 7/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 204 | $0 | 7/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 220 | $0 | 4/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 78 | $18K | 4/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 365 | $0 | 1/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 150 | $29K | 1/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.